Evidence map›Paper›PMID 39468648›Full record

ArticleBMC chemistry2024

Discovery of novel NLRP3 inhibitors based on machine learning and physical methods.

Tao Jiang, Shijing Qian, Jinhong Xu, Shuihong Yu, Yang Lu, Linsheng Xu, Xiaosi Yang

Abstract read
In one paragraph

Article in BMC chemistry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Tao Jiang *Anqing 116 Hospital, No.150 Shuangjing Street, Yingjiang District, Anqing City, Anhui Province, China.
Shijing Qian *Tongji Hospital of Tongji University, No. 389 Xincun Road, Putuo District, Shanghai City, China.
Jinhong XuAnqing 116 Hospital, No.150 Shuangjing Street, Yingjiang District, Anqing City, Anhui Province, China.
Shuihong YuSchool of Basic Medical Sciences, Anqing Medical College, No.1588, Jixian North Road,Yixiu District, Anqing City, Anhui Province, China.
Yang LuAnqing 116 Hospital, No.150 Shuangjing Street, Yingjiang District, Anqing City, Anhui Province, China.
Linsheng XuAnqing 116 Hospital, No.150 Shuangjing Street, Yingjiang District, Anqing City, Anhui Province, China. 987854635@qq.com.
Xiaosi YangSchool of Basic Medical Sciences, Anqing Medical College, No.1588, Jixian North Road,Yixiu District, Anqing City, Anhui Province, China. yxsi@aqmc.edu.cn.

Funding

the Academic sponsorship project for top talents in university disciplines (majors) gxbjZD2022105
6 · The paper itself

Abstract

The NLRP3 inflammasome plays a crucial role in inflammatory responses, particularly in alcohol-related liver disease (ALD). Given that NLRP3 has emerged as a potential therapeutic target for ALD, the development of effective inhibitors is of great importance. In this study, we trained 11 regression models, and the results showed that LightGBM, Random Forest, and XGBoost performed the best, achieving R² values of 0.774, 0.755, and 0.719, respectively. Using machine learning models and physical methods, we screened more than 11.5 million compounds from Asinex, Princeton, UkrOrgSynthesis, Chemdiv, Chembridge, Alinda, Enamine, and Lifechemicals, which led to the identification of 26 potential NLRP3 inhibitors. Furthermore, molecular dynamics simulations and MMGBSA binding energy calculations confirmed the stability of the interactions between NLRP3 and three key molecules: 19,655,631 (source Chembridge), 38,214,692 (source Chembridge), and Z1180203703 (source Enamine). Additionally, ADMET analysis revealed their favorable pharmacokinetic properties. This study provides insights and candidate molecules for discovering NLRP3 inhibitors, potentially applicable in treating related diseases.

Indexed as

Drug discoveryMachine learningMolecular dockingMolecular dynamics simulationNLRP3 inflammasomeNLRP3 inhibitors

Identifiers

PMID39468648
PMCPMC11520493

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.